Overview

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas
Collaborators:
Kansas Masonic Cancer Research Institute
Novartis
Treatments:
Docetaxel
Imatinib Mesylate